FindTrial
Sign In

Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT01949766
Enrollment
Unknown
Registered
2013-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2013-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Byler Disease

Brief summary

This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.

Interventions

DRUGGlycerol phenylbutyrate

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
6 Months to No maximum

Inclusion criteria

* Byler Disease * Cholestasis * Tolerance of Buphenyl therapy

Exclusion criteria

* Allergy/Hypersensitivity to RAVICTI

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026